BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 18086887)

  • 1. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.
    Jin Y; Zeng SX; Sun XX; Lee H; Blattner C; Xiao Z; Lu H
    Mol Cell Biol; 2008 Feb; 28(4):1218-29. PubMed ID: 18086887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 14-3-3Gamma inhibition of MDMX-mediated p21 turnover independent of p53.
    Lee JH; Lu H
    J Biol Chem; 2011 Feb; 286(7):5136-42. PubMed ID: 21148311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of MdmX on Mdm2-mediated downregulation of pRB.
    Uchida C; Miwa S; Isobe T; Kitagawa K; Hattori T; Oda T; Yasuda H; Kitagawa M
    FEBS Lett; 2006 Mar; 580(7):1753-8. PubMed ID: 16510145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
    Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
    Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation.
    Okamoto K; Kashima K; Pereg Y; Ishida M; Yamazaki S; Nota A; Teunisse A; Migliorini D; Kitabayashi I; Marine JC; Prives C; Shiloh Y; Jochemsen AG; Taya Y
    Mol Cell Biol; 2005 Nov; 25(21):9608-20. PubMed ID: 16227609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
    Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.
    Zhang Z; Wang H; Li M; Agrawal S; Chen X; Zhang R
    J Biol Chem; 2004 Apr; 279(16):16000-6. PubMed ID: 14761977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.
    Jin Y; Lee H; Zeng SX; Dai MS; Lu H
    EMBO J; 2003 Dec; 22(23):6365-77. PubMed ID: 14633995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
    Wang X
    Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
    Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.
    de Polo A; Luo Z; Gerarduzzi C; Chen X; Little JB; Yuan ZM
    J Mol Cell Biol; 2017 Apr; 9(2):154-165. PubMed ID: 27927748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance.
    Kulikov R; Boehme KA; Blattner C
    Mol Cell Biol; 2005 Aug; 25(16):7170-80. PubMed ID: 16055726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
    Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.
    Wang X; Wang J; Jiang X
    J Biol Chem; 2011 Jul; 286(27):23725-34. PubMed ID: 21572037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.